secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001599298-22-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Ankur Dhingra as CFO with $450k base salary
------------------------------------------------------------------------

- Ankur Dhingra named CFO effective May 31, 2022, replacing interim CFO Robert W. Duggan (who remains CEO).
- Annual base salary of $450,000; eligible for performance bonus up to 50% of base.
- Granted option to purchase 600,000 shares (10-year term, 4-year graded vesting, strike at grant-date close).
- Dhingra previously CFO at CareDx and held finance roles at Agilent Technologies; also oversees IT and HR.
- No written employment agreement; no family relationships or material transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/0001599298-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/smmt-20220601.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer